Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to analyse the concentration dopamine and serotonin in thrombocytes of patients with renal cell carcinoma and neuro-endocrine tumours compared to the concentrations of these catecholamines in healthy volunteers. The concentration dopamine and serotonin in thrombocytes with and without medication will also be evaluated.

Detailed Description
-----------------
To analyse the concentration catecholamines in thrombocytes of patients with clear cell renal cell carcinoma and low grade neuroendocrine tumours. To compare these concentrations with the concentrations catecholamines in thrombocytes of healthy controls. To analyse the concentration catecholamines in thrombocytes of patients with clear cell renal cell carcinoma and patients with low grade neuroendocrine tumours with and without medication.

Official Title
-----------------
Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.

Conditions
-----------------
Carcinoma, Carcinoma, Renal Cell, Neuroendocrine Tumors, Carcinoid Tumor, Pancreatic Islet Cell Tumors

Intervention / Treatment
-----------------
* Other: Blood sampling by vena punction.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years old or older. Patients with clear cell renal cell carcinoma with metastases or patients with a low-grade neuro-endocrine tumor with metastases. Written informed consent Exclusion Criteria: Use of L-dopa or SSRI. Patients with a second primary malignancy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group A<br>Patients with clear cell renal cell carcinoma with metastases. | Other: Blood sampling by vena punction.<br>* We obtain 10mL blood of the patients. The blood is obtained twice: once with angiogenesis inhibitors or mTOR inhibitors, and once without.<br>|
| Group B<br>Patients with low grade neuro-endocrine tumours with metastases. | Other: Blood sampling by vena punction.<br>* We obtain 10mL blood of the patients. The blood is obtained twice: once with angiogenesis inhibitors or mTOR inhibitors, and once without.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in concentrations DA and 5-HT in thrombocytes of patients with clear cell renal cell carcinoma and healthy controls, and patients with low grade neuroendocrine tumours and healthy controls. |  | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in concentrations DA and 5-HT in thrombocytes of patients with clear cell renal cell carcinoma and low grade neuroendocrine tumours with and without medication. |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Angiogenesis Inhibitors, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Neoplasms, Adenocarcinoma, Kidney Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Kidney Diseases, Angiogenesis Inducing Agents, Biological Markers